Skip to main content
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc. — Investor Relations & Filings

Ticker · INKT ISIN · US6036931029 LEI · 529900Z7778N8ZY89B90 US Manufacturing
Open in API
Filings indexed 226 across all filing types
Latest filing 2024-03-06 Director's Dealing
Country US United States of America
Listing US INKT

About MiNK Therapeutics, Inc.

https://www.minktherapeutics.com

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. The company's platform harnesses the dual properties of iNKT cells, which combine the potent cytotoxicity of natural killer (NK) cells with the lasting memory response of T cells to enhance both innate and adaptive immunity. Its lead product candidate, AGENT-797, is an off-the-shelf therapy administered without requiring lymphodepletion or HLA matching. It is currently in clinical trials for solid tumors, severe acute respiratory distress syndrome (ARDS), and Graft versus Host Disease (GvHD). MiNK is also developing a next-generation technology platform for engineered iNKT cells and bispecific iNKT cell engagers for precision targeting.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2024-03-06 English
4
Director's Dealing
2024-03-06 English
8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The content specifically details notices received from Nasdaq regarding the company's failure to meet listing requirements (Minimum Value of Listed Securities and Minimum Bid Price) and the potential consequences including delisting. This is a regulatory announcement about listing compliance issues, not a full financial report or earnings release. The document is not a report publication announcement or certification but a formal regulatory filing about delisting notices. Therefore, the appropriate classification is Delisting Announcement (DLST). The document length and detail support this classification with high confidence.
2024-02-29 English
SC 13D
Major Shareholding Notification
2024-02-15 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement involving a Convertible Promissory Note Purchase Agreement and related financial obligations. This is an update on the company's financing activities, specifically a new financing agreement and related terms. The document is not a full financial report, earnings release, or management discussion, but rather a specific announcement about capital raising and financing terms. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4435 characters, which is consistent with a detailed 8-K filing but not a full annual or quarterly report. Confidence is high given the clear description of a financing agreement and related obligations.
2024-02-14 English
4
Director's Dealing
2024-01-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.